Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

The Ohio State University Wexner Medical Center – James Cancer Hospital

Key Takeaway: The article provides an overview of the Ohio State University Wexner Medical Center and James Cancer Hospital, detailing their management structure, collaborations, patient studies, and pipeline of drugs. It highlights current studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with the company's drug development efforts. Additionally, it mentions various resources available for investors and patients.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 47 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by the Ohio State Wexner Medical Center?

The center sponsors studies including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What drugs are included in the pipeline overview?

The pipeline includes Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

What resources are available for investors?

Investors can access press releases, financial information, SEC filings, and annual reports.

What is the focus of the TakeAim studies?

The TakeAim studies focus on various types of lymphoma and leukemia treatments.

Last updated: Oct 23, 2024